Elicio reports Q2 2026 results, plans new Phase 1 combination trial after complete responses
Elicio said it will start a Phase 1 study combining ELI-002 7P with a RAS inhibitor in metastatic pancreatic cancer in Q4 2026 after seeing complete responses, while its Phase 2 trial missed its main goal.
SEC filing